A pharmaceutical composition comprises a Parkinson's disease treating effective amount of a combination of a forebrain selective NMDA antagonist and an excitatory feedback enhancing agent with a pharmaceutically acceptable diluent or carrier and optionally carbidopa. The forebrain selective NMDA antagonist can be (+)-(1S,2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol, (1S,2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol and (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman-4,7-diol and the excitatory feedback enhancing agent is levodopa.
Pharmaceutical compositions comprising a forebrain selective NMDA antagonist and an excitatory feedback enhancing agent used in treating Parkinsons Disease